2023
Vigorous Exercise in Patients With Hypertrophic Cardiomyopathy
Lampert R, Ackerman M, Marino B, Burg M, Ainsworth B, Salberg L, Tome Esteban M, Ho C, Abraham R, Balaji S, Barth C, Berul C, Bos M, Cannom D, Choudhury L, Concannon M, Cooper R, Czosek R, Dubin A, Dziura J, Eidem B, Emery M, Estes N, Etheridge S, Geske J, Gray B, Hall K, Harmon K, James C, Lal A, Law I, Li F, Link M, McKenna W, Molossi S, Olshansky B, Ommen S, Saarel E, Saberi S, Simone L, Tomaselli G, Ware J, Zipes D, Day S, Abrahms D, Ashley E, Aziz P, Batra A, Cerrone M, Colan S, Erickson C, Ferhaan A, Gollob M, Johnsrude C, Kannankeril P, Kanter R, Li W, Masri A, Murphy A, Nandi D, Perez M, Perry J, Popjes E, Rao R, Rosenthal D, Sanatani S, Semsarian C, Shah M, Skinner J, Tardif J, Towbin J, Turer A, Webster G, Wever-Pinzon O, Wong T. Vigorous Exercise in Patients With Hypertrophic Cardiomyopathy. JAMA Cardiology 2023, 8: 595-605. PMID: 37195701, PMCID: PMC10193262, DOI: 10.1001/jamacardio.2023.1042.Peer-Reviewed Original ResearchConceptsComposite end pointVigorous-intensity exerciseHypertrophic cardiomyopathyVigorous exerciseEnd pointCohort studyExercise categoriesVentricular arrhythmiasPhysical activityPrimary composite end pointMultivariate Cox regression analysisAdjusted hazard ratioProspective cohort studyCox regression analysisLeft ventricular hypertrophyLife-threatening arrhythmiasSudden cardiac arrestImplantable cardioverter defibrillatorHigh rateHCM centersNonvigorous activitiesObservational registryAppropriate shocksExperienced centersHazard ratio
2021
Symptomatic Acute Myocarditis in 7 Adolescents After Pfizer-BioNTech COVID-19 Vaccination
Marshall M, Ferguson ID, Lewis P, Jaggi P, Gagliardo C, Collins JS, Shaughnessy R, Caron R, Fuss C, Corbin KJE, Emuren L, Faherty E, Hall EK, Di Pentima C, Oster ME, Paintsil E, Siddiqui S, Timchak DM, Guzman-Cottrill JA. Symptomatic Acute Myocarditis in 7 Adolescents After Pfizer-BioNTech COVID-19 Vaccination. Pediatrics 2021, 148: e2021052478. PMID: 34088762, DOI: 10.1542/peds.2021-052478.Peer-Reviewed Original ResearchConceptsPfizer-BioNTech COVID-19 vaccinationCOVID-19 vaccinationAcute myocarditisClinical courseLate gadolinium enhancement (LGE) characteristicsPolymerase chain reaction test resultsTranscription polymerase chain reaction (RT-PCR) test resultsVaccine Adverse Event Reporting SystemCoronavirus disease 2019 (COVID-19) vaccinationAcute COVID-19Multisystem inflammatory syndromeAdverse Event Reporting SystemImportant adverse eventsTime of presentationNonsteroidal antiinflammatory drugsHealthy male adolescentsGadolinium enhancement characteristicsEvent Reporting SystemReaction test resultsChest painElevated troponinInflammatory syndromeIntravenous immunoglobulinAdverse eventsSecond dose
2019
Baseline Characteristics of the VANISH Cohort
Axelsson Raja A, Shi L, Day SM, Russell M, Zahka K, Lever H, Colan SD, Margossian R, Hall EK, Becker J, Jefferies JL, Patel AR, Choudhury L, Murphy AM, Canter C, Bach R, Taylor M, Mestroni L, Wheeler MT, Benson L, Owens AT, Rossano J, Lin KY, Pahl E, Pereira AC, Bundgaard H, Lewis GD, Vargas JD, Cirino AL, McMurray JJV, MacRae CA, Solomon SD, Orav EJ, Braunwald E, Ho CY. Baseline Characteristics of the VANISH Cohort. Circulation Heart Failure 2019, 12: e006231. PMID: 31813281, PMCID: PMC7219518, DOI: 10.1161/circheartfailure.119.006231.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAngiotensin II Type 1 Receptor BlockersBrazilCanadaCardiomyopathy, HypertrophicChildDenmarkDisease ProgressionDouble-Blind MethodFemaleGenetic Predisposition to DiseaseHumansMaleMiddle AgedMutationPhenotypeRecovery of FunctionSarcomeresTime FactorsTreatment OutcomeUnited StatesValsartanYoung AdultConceptsAngiotensin receptor blockersHypertrophic cardiomyopathyReceptor blockersBaseline characteristicsImaging abnormalitiesPrimary cohortMutation carriersNew York Heart Association class IINew York Heart Association classFunctional class II symptomsOlder ageClass II symptomsNonobstructive hypertrophic cardiomyopathyNormal functional capacityPrevious trialsVentricular wall thicknessPeak oxygen consumptionPlacebo-controlled designCardiac magnetic resonanceGene mutation carriersLate gadolinium enhancementVANISH trialAdvanced diseaseAssociation classVentricular hypertrophy
2016
Vitamin D Status After Cardiopulmonary Bypass in Children With Congenital Heart Disease
Zahr R, Faustino EV, Carpenter T, Kirshbom P, Hall EK, Fahey JT, Kandil SB. Vitamin D Status After Cardiopulmonary Bypass in Children With Congenital Heart Disease. Journal Of Intensive Care Medicine 2016, 32: 508-513. PMID: 27251108, DOI: 10.1177/0885066616652077.Peer-Reviewed Original ResearchConceptsCongenital heart diseasePg/mLCardiopulmonary bypassVitamin D binding proteinD binding proteinHeart diseaseAlbumin levelsTime pointsVitamin D deficiencyVitamin D statusProspective observational studyMean levelsFree fractionD deficiencyD statusDihydroxyvitamin DObservational studySurgeryBinding proteinBypassDiseaseMeasures analysisChildrenDeficiencyML
2015
Effect of the decrease in dialysate sodium in pediatric patients on chronic hemodialysis
Marsenic O, Anderson M, Couloures KG, Hong WS, Hall E, Dahl N. Effect of the decrease in dialysate sodium in pediatric patients on chronic hemodialysis. Hemodialysis International 2015, 20: 277-285. PMID: 26663617, DOI: 10.1111/hdi.12384.Peer-Reviewed Original ResearchConceptsPediatric patientsDialysate sodiumPediatric HD populationPediatric hemodialysis populationStandard HD sessionInterdialytic weight gainMEq/LChronic HDHemodialysis populationChronic hemodialysisHD sessionHD populationInterdialytic periodAdult studiesPatientsWeight gainStudy periodLack of concordanceFurther studiesSodium gradientFirst reportHypertensionPredialysisHemodialysisPopulation
2011
Doppler tissue imaging in children following cardiac transplantation: A comparison to catheter derived hemodynamics
Goldberg DJ, Quartermain MD, Glatz AC, Hall EK, Davis E, Kren SA, Hanna BD, Cohen MS. Doppler tissue imaging in children following cardiac transplantation: A comparison to catheter derived hemodynamics. Pediatric Transplantation 2011, 15: 488-494. PMID: 21518161, PMCID: PMC3140578, DOI: 10.1111/j.1399-3046.2011.01503.x.Peer-Reviewed Original ResearchConceptsHigh-grade cellular rejectionTricuspid EHeart transplantationCellular rejectionFilling pressureMean RAPVentricular filling pressurePediatric heart transplantationMean PCWPCardiac transplantationHeart transplantDoppler tissueElevated PCWPMyocardial velocitiesProspective analysisTransplantationRejection statusPCWPChildrenSubjectsPrevious studiesTransplantHemodynamicsRejection
2010
Brain‐type natriuretic peptide correlates with right heart pressures in a cross section of pediatric heart transplant patients
Hall EK, Glatz AC, Quartermain MD, Ravishankar C, Kaufman B, Cohen MS, Hanna BD, Goldberg DJ. Brain‐type natriuretic peptide correlates with right heart pressures in a cross section of pediatric heart transplant patients. Pediatric Transplantation 2010, 15: 70-74. PMID: 21199206, DOI: 10.1111/j.1399-3046.2010.01421.x.Peer-Reviewed Original ResearchConceptsBrain-type natriuretic peptide levelsRejection gradeHeart transplantationHemodynamic measurementsSerum brain-type natriuretic peptide levelsPediatric heart transplant patientsCellular rejection gradeInvasive hemodynamic measurementsNatriuretic peptide levelsHeart transplant patientsRight heart pressuresRight-sided pressuresMonitoring of childrenBNP correlatesCellular rejectionTransplant patientsAdult patientsCardiac catheterizationHeart failureHeart pressuresPediatric patientsHemodynamic parametersPeptide levelsPg/Peptide correlates